现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2014年
6期
1307-1309
,共3页
许晓峰%李硕%熊伟坚%陆钢%赵忠清%胡开闯
許曉峰%李碩%熊偉堅%陸鋼%趙忠清%鬍開闖
허효봉%리석%웅위견%륙강%조충청%호개틈
中晚期鼻咽癌%同步放化疗%诱导化疗%奈达铂
中晚期鼻嚥癌%同步放化療%誘導化療%奈達鉑
중만기비인암%동보방화료%유도화료%내체박
advanced nasopharyngeal carcinoma%concurrent radiotherapy and chemotherapy%induction chemothera-py%nedaplatin
目的:观察奈达铂每周同步放化疗与奈达铂﹢氟尿嘧啶诱导化疗联合放疗治疗中晚期鼻咽癌的近期疗效和毒副反应。方法:52例中晚期鼻咽癌患者随机分为同步放化疗组( A组)和诱导化疗﹢放疗组( B组)。A组接受奈达铂单药每周一次同步化疗,B组接受奈达铂联合氟尿嘧啶诱导化疗两周期﹢放疗。结果:放疗结束及3个月后近期疗效观察。放疗结束时有效率A组为95.8%,B组为92.8%,完全缓解率A组为79.2%,B组为60.7%。放疗3个月后A组有效率为95.8%,B组为96.4%,完全缓解率A组为83.3%,B组为82.1%。毒性反应:III-IV级口腔黏膜反应A组为12.5%,B组为7.1%;III-IV级白细胞及粒细胞减少A组为16.7%,B组为7.1%。结论:对中晚期鼻咽癌,含奈达铂方案同步放化疗近期疗效优于诱导化疗﹢放疗,病人耐受性较好,远期疗效还有待进一步观察。
目的:觀察奈達鉑每週同步放化療與奈達鉑﹢氟尿嘧啶誘導化療聯閤放療治療中晚期鼻嚥癌的近期療效和毒副反應。方法:52例中晚期鼻嚥癌患者隨機分為同步放化療組( A組)和誘導化療﹢放療組( B組)。A組接受奈達鉑單藥每週一次同步化療,B組接受奈達鉑聯閤氟尿嘧啶誘導化療兩週期﹢放療。結果:放療結束及3箇月後近期療效觀察。放療結束時有效率A組為95.8%,B組為92.8%,完全緩解率A組為79.2%,B組為60.7%。放療3箇月後A組有效率為95.8%,B組為96.4%,完全緩解率A組為83.3%,B組為82.1%。毒性反應:III-IV級口腔黏膜反應A組為12.5%,B組為7.1%;III-IV級白細胞及粒細胞減少A組為16.7%,B組為7.1%。結論:對中晚期鼻嚥癌,含奈達鉑方案同步放化療近期療效優于誘導化療﹢放療,病人耐受性較好,遠期療效還有待進一步觀察。
목적:관찰내체박매주동보방화료여내체박﹢불뇨밀정유도화료연합방료치료중만기비인암적근기료효화독부반응。방법:52례중만기비인암환자수궤분위동보방화료조( A조)화유도화료﹢방료조( B조)。A조접수내체박단약매주일차동보화료,B조접수내체박연합불뇨밀정유도화료량주기﹢방료。결과:방료결속급3개월후근기료효관찰。방료결속시유효솔A조위95.8%,B조위92.8%,완전완해솔A조위79.2%,B조위60.7%。방료3개월후A조유효솔위95.8%,B조위96.4%,완전완해솔A조위83.3%,B조위82.1%。독성반응:III-IV급구강점막반응A조위12.5%,B조위7.1%;III-IV급백세포급립세포감소A조위16.7%,B조위7.1%。결론:대중만기비인암,함내체박방안동보방화료근기료효우우유도화료﹢방료,병인내수성교호,원기료효환유대진일보관찰。
Objective:To compare the effect and toxic reaction of concurrent radiotherapy and chemotherapy or in-duction chemotherapy with nedaplatin for advanced nasopharyngeal carcinoma. Methods:All 52 patients with ad-vanced nasopharyngeal carcinoma were randomized into two groups:concurrent radiotherapy and chemotherapy group ( Group A),induction chemotherapy group( Group B). The patients in Group A were treated by weeky nedaplatin bi-side radiotherapy,the patients in Group B treated by 2 cycles of induction chemotherapy with nedaplatin plus 5-flu-orourac before radiotherapy. Results:The recent effect:the end of radiotherapy an after three months,in Group A,CR rates were 79. 2% and 83. 3%,CR﹢PR rates were both 95. 8%. In Group B,CR rates were 60. 7% and 82. 1%,CR A were 12. 5% and 16. 7%,in Group B were both 7. 1%. Conclusion:For advanced nasopharyngeal carcinoma,concurrent radiotherapy and chemotherapy with nedaplatin is more effective than induction chemotherapy,patients were well tolerated.